Additional extension of the mathematical model for BCG immunotherapy of bladder cancer and its validation by auxiliary tool

DOI10.1515/IJNSNS-2018-0181zbMath1464.92125OpenAlexW2964023356WikidataQ127444092 ScholiaQ127444092MaRDI QIDQ2296074

Svetlana Bunimovich-Mendrazitsky, Sarel Halachmi, Ekaterina Guzev

Publication date: 17 February 2020

Published in: International Journal of Nonlinear Sciences and Numerical Simulation (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1515/ijnsns-2018-0181

zbMATH Keywords

mathematical modelingbladder cancerBCG and IL-2 combined therapyBCG immunotherapytumor-immune dynamics

Mathematics Subject Classification ID

Medical applications (general) (92C50) Qualitative investigation and simulation of ordinary differential equation models (34C60)

Related Items (3)

Mathematical model for BCG-based treatment of type 1 diabetes ⋮ TREATMENT OF BLADDER CANCER USING BCG IMMUNOTHERAPY: PDE MODELING ⋮ PDE modeling of bladder cancer treatment using BCG immunotherapy

Cites Work

• Unnamed Item
• Unnamed Item
• Unnamed Item
• Mathematical model of pulsed immunotherapy for superficial bladder cancer
• Nonlinear dynamics of immunogenic tumors: Parameter estimation and global bifurcation analysis
• The human immune response to \textit{Mycobacterium tuberculosis} in lung and lymph node
• A mathematical model of combined \textit{bacillus Calmette-Guerin} (BCG) and interleukin (IL)-2 immunotherapy of superficial bladder cancer
• Mathematical model of BCG immunotherapy in superficial bladder cancer
• Cellular Immunotherapy for High Grade Gliomas: Mathematical Analysis Deriving Efficacious Infusion Rates Based on Patient Requirements
• Improving Bacillus Calmette-Guérin (BCG) immunotherapy for bladder cancer by adding interleukin 2 (IL-2): a mathematical model
• USING COMPUTER SIMULATIONS FOR EVALUATING THE EFFICACY OF BREAST CANCER CHEMOTHERAPY PROTOCOLS

This page was built for publication: Additional extension of the mathematical model for BCG immunotherapy of bladder cancer and its validation by auxiliary tool